The effect of the options, if all exercised, would be to increase the issued share capital by 2.53% and raise £672,838 gross for the Company.
| Daily Average Per Year Since Listing |
Daily Average Per Month in 2010 |
||||
| 2007 | 219,000 | Jan | 130,000 | ||
| 2008 | 126,000 | ||||
| 2009 | 118,000 | ||||
The number of ordinary shares subject to options granted under the Share Option Schemes of the Company were:
| Grant | Exercise period (incl) | Exercise Price/share | No of share options granted |
Cash to Company on exercise |
| 7/06 | 2/08 - 1/13 | 74.5p | 200,000 | £149,000 |
| 7/07 | 2/09 - 1/14 | 56.25p | 300,000 | £168,750 |
| 6/08 | 2/10 - 1/15 | 41.75p | 290,000 | £121,075 |
| 7/09 | 8/11 - 7/16 | 24.25p | 965,000 | £234,013 |
| Totals | 1,755,000 | £672,838 |
Further details of share options issued before December 2009 can be obtained from the Company's Annual Report 2009 which can be found by following this link.
Page last up-dated: 2 March 2010
Page last reviewed: 2 March 2010
Major Shareholders
(as at 18 November 2009)
Institutions holding more than 3% of the share capital of Futura were:
- Brookwell Ltd 4.79%
- Gartmore Investment Management 4.42%
Other shareholders holding more than 3% of the share capital of Futura were:
- RA Lamb 7.36%
- WT Lamb Investments Limited 6.45%
- Medinvest Holdings Limited 5.92%
- Christopher John Crabtree 5.11%
- P McMahon 3.58%
Shares not in public hands
In the terms of the AIM Rules published in February 2007 and insofar as it is aware, at 18 November 2009, 2.42% of the Company's AIM securities were not in public hands.
There are no restrictions on the transfer of Futura Medical securities.